BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

G. Mann,G. Pupo,A. Campain,Candace D. Carter,Sarah-Jane Schramm,S. Pianova,S. Gerega,C. de Silva,K. Lai,J. Wilmott,M. Synnott,P. Hersey,R. Kefford,J. Thompson,Y. H. Yang
DOI: https://doi.org/10.1038/jid.2012.283
IF: 7.59
2013-02-01
Journal of Investigative Dermatology
Abstract:
What problem does this paper attempt to address?